Welcome to E-Menai

took ambien with alcohol According to a recent peer reviewed publication authored by leading migraine researchers, more than 70 percent of patients indicated that they were less than completely satisfied with their current treatment. is a specialty pharmaceutical company focused primarily in the area of cardiology. Acura and King are currently evaluating the FDA's Complete Response Letter, and at this stage believe they can respond to the issues raised without conducting any additional studies. Examples of forward looking statements in this press release include statements concerning the Companies' expectations regarding the timing or content of their took ambien with alcohol response to the FDA concerning the Complete Response Letter and the Companies' expectations regarding any meeting with the FDA to discuss the Complete Response Letter. Other important factors that may cause actual results to differ materially from the forward-looking statements are discussed in the "Risk Factors" section and other sections of each of the Companies' Annual Reports on Form 10-K for the year ended December 31, 2008 and their respective Quarterly Reports on Form 10-Q for the quarter ended March 31, 2009, each of which is on file with the U.